Business Description
Renalytix PLC
ISIN : US75973T1016
Share Class Description:
STU:2O90: ADRTotal Employee Number:
47Description
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.07 | |||||
Equity-to-Asset | -0.12 | |||||
Debt-to-Equity | -4.84 | |||||
Debt-to-EBITDA | -0.28 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -47.96 | |||||
Beneish M-Score | -4.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -37.6 | |||||
3-Year EBITDA Growth Rate | 53.8 | |||||
3-Year EPS without NRI Growth Rate | 57.7 | |||||
3-Year FCF Growth Rate | 54.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.57 | |||||
Quick Ratio | 1.52 | |||||
Cash Ratio | 1.15 | |||||
Days Inventory | 63.93 | |||||
Days Sales Outstanding | 90.26 | |||||
Days Payable | 868.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -64.2 | |||||
Shareholder Yield % | -73.04 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 45.51 | |||||
Operating Margin % | -505.64 | |||||
Net Margin % | -602.45 | |||||
EBITDA Margin % | -629.09 | |||||
FCF Margin % | -397.39 | |||||
OCF Margin % | -394.4 | |||||
ROA % | -211.28 | |||||
ROIC % | -1123.52 | |||||
3-Year ROIIC % | -311.21 | |||||
ROC (Joel Greenblatt) % | -3649.29 | |||||
ROCE % | -475.02 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.5 | |||||
EV-to-EBIT | -0.77 | |||||
EV-to-EBITDA | -0.77 | |||||
EV-to-Revenue | 4.88 | |||||
EV-to-Forward-Revenue | 1.82 | |||||
EV-to-FCF | -1.23 | |||||
Price-to-GF-Value | 0.56 | |||||
Earnings Yield (Greenblatt) % | -129.87 | |||||
FCF Yield % | -79.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Renalytix PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.84 | ||
| EPS (TTM) (€) | -1.721 | ||
| Beta | 1.6926 | ||
| 3-Year Sharpe Ratio | -0.33 | ||
| 3-Year Sortino Ratio | -0.61 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 2.7 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 2.7 - 2.7 | ||
| Shares Outstanding (Mil) | 8.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Renalytix PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Renalytix PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| General meeting for 2026 | 2026-12-09 10:00 | In 145 days | ||
| Annual report for 2026 | 2026-11-04 | In 109 days | ||
| Fourth quarter earnings results for 2026 | 2026-11-03 | In 108 days | ||
| Third quarter earnings conference call for 2026 | 2026-05-29 | 2.70 (+0.00%) | ||
| Third quarter earnings results for 2026 | 2026-05-29 | 2.70 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-03-31 | 2.70 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-03-31 | 2.70 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-03-26 | 2.70 (+0.00%) | ||
| 0.04:1 Stock Split | 2025-12-16 | 2.70 (+0.00%) | ||
| General meeting for 2025 | 2025-12-09 10:00 | 2.70 (+0.00%) |
Show
Entries
Renalytix PLC Frequently Asked Questions
What is Renalytix PLC(STU:2O90)'s stock price today?
The current price of STU:2O90 is €2.70. The 52 week high of STU:2O90 is €2.70 and 52 week low is €2.70.
When is next earnings date of Renalytix PLC(STU:2O90)?
The next earnings date of Renalytix PLC(STU:2O90) is 2026-11-03 Est..
Does Renalytix PLC(STU:2O90) pay dividends? If so, how much?
Renalytix PLC(STU:2O90) does not pay dividend.
Press Release
Articles on Renalytix PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers